Syndax Pharmaceuticals, Inc. Payments to Acquire Assets, Investing Activities
Syndax Pharmaceuticals, Inc. (SNDX) reported Payments to Acquire Assets, Investing Activities of $40.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAssetsInvestingActivities · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. payments to acquire assets, investing activities for the quarter ending 2025-09-30 was $131.00K.
| Period end | Payments to Acquire Assets, Investing Activities 3 month | Payments to Acquire Assets, Investing Activities 6 month | Payments to Acquire Assets, Investing Activities 9 month |
|---|---|---|---|
| 2026-06-30 | $40.00K 10-Q · filed 2026-08-04 | ||
| 2025-09-30 | $131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $131.00K 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |